BSX

Business Context and Reporting Period

Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2001
Business Overview: A worldwide developer, manufacturer, and marketer of medical devices for less invasive procedures, operating in four geographic segments: United States, Europe, Japan, and Inter-Continental.

Key Financial Metrics

Note: Total Debt for Q1 2001 calculated as Commercial Paper ($29M) + Bank Obligations ($311M) + Long-term Debt ($568M) = $908M. However, the text highlights $292M in revolving credit and $29M in commercial paper as key liquidity components. The balance sheet lists Total Current Liabilities of $899M and Long-term Debt of $568M.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 4% to $654 million. Excluding a $24 million adverse foreign currency impact, sales would have been flat at $678 million. International revenues dropped 9% to $263 million, while U.S. revenues remained stable at $391 million.
• Profitability Shift: The company reported a net loss of $5 million compared to net income of $106 million in the prior year. This reversal was primarily driven by a $79 million charge for purchased research and development (R&D) related to three acquisitions (EPI, CI, Quanam) and $13 million in expenses related to the global operations plan.
• Margin Compression: Gross margin decreased from 68.6% to 66.1% due to the global operations plan expenses and the launch of higher-costing coronary stent systems.
• Acquisition Activity: The company completed three acquisitions in Q1 2001 totaling approximately $103 million (cash and stock) and announced a fourth acquisition (Interventional Technologies, Inc.) on April 2, 2001, with an obligation of approximately $345 million in cash plus earn-outs.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Global Operations Plan: The company expects to record an additional $50 million in pre-tax expenses related to the plant optimization initiative for the remainder of 2001. Total cash outlays for this initiative are estimated at $115 million, with $70 million expected in the remainder of 2001. Management projects pre-tax operating savings of $100 million in 2001 relative to 1999.
• Product Pipeline: The company received FDA approval for four NIR(R) coronary stent systems and a new balloon catheter. However, stent revenues for 2001 are expected to be negatively impacted by market volatility and competitive pricing pressures.
• Acquisition Integration: Management anticipates earn-out payments of $100 million to $200 million in 2001 for recent acquisitions. Capital expenditures for the remainder of 2001 are estimated at $70 million.

Material Risks and Contingencies

• Medinol Litigation: On April 5, 2001, Medinol Ltd. (exclusive supplier of NIR(R) stents) sued the company for fraud and breach of contract, seeking to end the company's right to distribute Medinol stents. The company has countersued. This poses a significant supply chain risk given $132 million in NIR(R) inventory and $25 million in purchase commitments.
• Patent Litigation: A jury found the company's NIR(R) stent infringed a Johnson & Johnson patent, awarding approximately $324 million in damages. A final decision is pending post-trial motions. The company estimates a potential loss range of $0 to $344 million plus interest for this and other contingencies.
• Regulatory and Market Risks: Risks include delays in regulatory approvals for new stent platforms, price compression due to managed care trends, and foreign currency fluctuations (hedging program covers forecasted transactions but unhedged portions remain exposed).

Investor Verification Checklist

• Medinol Dispute Status: Verify the current status of the Medinol lawsuit and any potential impact on the supply of NIR(R) stents, which represent ~15% of worldwide sales.
• Johnson & Johnson Litigation Outcome: Monitor the final court decision regarding the $324 million jury verdict for patent infringement.
• Global Operations Plan Execution: Track the realization of the projected $100 million in annualized savings against the $50 million in remaining 2001 restructuring costs.
• Acquisition Integration: Assess the financial impact of the $345 million IVT acquisition and the $100-$200 million in expected earn-out payments.
• Inventory Levels: Review the $132 million NIR(R) stent inventory levels and the company's ability to manage inventory mix during the transition to new products.